Larimar Seeks Faster FDA Approval For Frataxin Replacement As Confirmatory Testing Continues
The company projects cash into late second quarter 2027 and targets a U.S. launch in the third quarter, if approved.
Larimar Therapeutics, which is developing a protein-replacement treatment for Friedreich’s ataxia, completed its approval application Monday for nomlabofusp, seeking accelerated FDA approval while a confirmatory trial enrolls patients. The application asks regulators to consider increased frataxin in skin as a potential substitute measure for clinical benefit.
Replacing The Protein Patients Lack
Nomlabofusp is designed to deliver human frataxin to mitochondria inside cells through injections under the skin. Friedreich’s ataxia is a genetic disease caused by too little of that essential protein; Larimar has devoted substantially all its resources to the drug and supporting operations.
The company’s announcement describes earlier FDA feedback that the evidence appeared capable of supporting an application and review. The agency was willing to consider frataxin as a potential substitute measure, but approval remains a decision for the review process.
Larimar Chief Executive Officer Carole Ben-Maimon said, “It is important to note that patients with FA are expected to experience continued neurologic decline, not improvement.”
Encouraging Data, Serious Allergic Reactions
The application draws on previously reported results from an ongoing study without a placebo group. At one year, all nine participants with evaluable skin measurements had frataxin levels in the range expected among carriers who have no symptoms.
A clinical disability rating improved by an average of 1.0 point among 13 treated participants at one year, compared with 1.6-point worsening in an external natural-history group. At 18 months, seven treated participants improved by 2.3 points; the company reported a 4.6-point advantage against a calculated external comparison. These are directional findings against an outside reference population, rather than results from a randomized placebo comparison.
June results included 10 anaphylaxis cases, nine in participants previously exposed to nomlabofusp. All recovered without lasting effects. In total, 21 participants discontinued, including three with generalized hives, three with other adverse events and five for reasons unrelated to treatment, primarily logistics.
A Trial And A Cash Deadline
The enrolling confirmatory study, FORWARD-FA, plans to test daily injections against placebo for 18 months in 100–150 participants. It starts with participants able to walk who are ages 12–40; children ages 2–11 will be added after their dose is confirmed. Approximately two thirds of participants are expected to be younger than 21.
Larimar’s corporate presentation puts preliminary, unaudited cash and investments at approximately $128.7 million on September 30, 2026. That estimate remains subject to quarter-end closing adjustments. Management projects funding into late second quarter 2027.
The company targets application acceptance in early 2027 and a safety update in the first quarter. Its schedule includes potential U.S. approval in mid-2027 and a third-quarter launch contingent on approval, along with obtaining and selling a rare pediatric disease priority review voucher if approved.
Larimar also plans to pursue marketing applications in the EU, UK, Canada and Australia during 2027–2028. Ben-Maimon said, “In parallel, we continue to evaluate options to optimize our global commercialization strategy.”
The next regulatory milestone is acceptance of the application, which Larimar targets for early 2027; completing the submission does not guarantee acceptance or approval.
Sources
- 8-K Filing — Larimar Therapeutics, Inc. (LRMR) — SEC EDGAR
- Exhibit lrmr-ex99_1.htm — Larimar Therapeutics, Inc. 8-K exhibit — SEC EDGAR
- Exhibit lrmr-ex99_2.htm — Larimar Therapeutics, Inc. 8-K exhibit — SEC EDGAR
- Larimar Therapeutics Completes Rolling BLA Submission Seeking Accelerated Approval of Nomlabofusp for Friedreich’s Ataxia — Yahoo Finance
- Larimar Therapeutics to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference — Yahoo Finance
- Larimar Therapeutics Completes Rolling BLA Submission — globenewswire.com
- Larimar Therapeutics Announces Three Poster Presentations — globenewswire.com
- Larimar Therapeutics to Participate in the Guggenheim 3rd — globenewswire.com